サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793664

経口タンパク質とペプチドの世界市場

Oral Proteins and Peptides

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
経口タンパク質とペプチドの世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

経口タンパク質とペプチドの世界市場は2030年までに20億米ドルに到達

2024年に13億米ドルと推定される経口タンパク質とペプチドの世界市場は、分析期間2024-2030年にCAGR 7.4%で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるカルシトニン薬剤タイプは、CAGR 6.1%を記録し、分析期間終了時には7億6,250万米ドルに達すると予測されます。インスリン製剤タイプの成長率は、分析期間中CAGR 9.6%と推定されます。

米国市場は3億5,160万米ドルと推定、中国はCAGR11.3％で成長予測

米国の経口タンパク質とペプチド市場は、2024年に3億5,160万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを11.3%として、2030年までに4億1,190万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.0%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界の経口タンパク質とペプチド市場- 主要動向と促進要因まとめ

なぜタンパク質とペプチドの経口投与は技術的に困難なままなのか？

タンパク質とペプチドは、消化器系での本質的な安定性に乏しい繊細な生体分子です。経口投与された場合、それらは胃酵素と過酷なpH条件による急速な分解に直面し、次いで分子サイズが大きく親水性のため腸管吸収が制限されます。このような障壁により、これまで治療用タンパク質の経口投与は制限され、そのほとんどが非経口投与に移行してきました。しかし、最近の科学の進歩により、経口デリバリーがより確かなものとなりつつあり、ペプチドベースの経口医薬品開発への新たな投資を促しています。

経口投与の動機は強く、特に糖尿病、成長障害、ホルモン欠乏症のような長期にわたる治療には有効です。患者は、利便性、快適性、注射に関連する合併症のリスク低減のために、注射よりも経口療法を好みます。それゆえ製薬業界は、ペプチド構造を安定化させ、全身吸収のために粘膜輸送を促進するアプローチに積極的に取り組んでいます。

どのような製剤技術が消化管からの全身吸収を可能にしているのか？

ペプチドやタンパク質の経口送達を可能にするために、いくつかの製剤戦略が活発に開発されています。腸溶性コーティングカプセルや酵素阻害剤の使用は、薬剤が腸に到達するまで保護するのに役立ちます。中鎖脂肪酸や胆汁酸塩のような吸収促進剤は、腸管内壁のタイトジャンクションを緩め、一時的に透過性を高めるために使用されます。ナノ粒子、自己乳化型ドラッグデリバリーシステム（SEDDS）、脂質ベースの製剤などのキャリアシステムは、薬物の溶解性と安定性を改善するために設計されています。

浸透性を高めるマイクロ容器、粘着フィルム、経細胞トランスポーターなどの技術は、安定した安全な吸収を達成するために改良されています。環化やD-アミノ酸置換を含むペプチドの構造修飾は、生物学的活性に影響を与えることなく酵素切断に対する耐性を向上させる。これらの方法によって、より多くのペプチド医薬品が治療効果に十分なバイオアベイラビリティ・レベルを達成できるようになっています。

どの治療薬が開発をリードし、イノベーションはどこに集中しているのか？

糖尿病と代謝性疾患は、経口ペプチド開発の主要な治療分野です。2型糖尿病に対するGLP-1受容体作動薬である経口セマグルチドは、最も注目すべき商業的成功例であり、この分野でのブレークスルーを示しています。同様の取り組みが、骨粗鬆症や甲状腺関連疾患に対するインスリン、副甲状腺ホルモン、カルシトニンの経口製剤をターゲットにしています。

バイオ医薬品企業もまた、関節リウマチや潰瘍性大腸炎などの疾患に対して、ペプチドベースの免疫療法薬や抗炎症薬の経口投与を模索しています。北米と一部の欧州諸国は、強力な研究開発インフラと規制当局の関与により、技術革新をリードしています。新興国は、費用対効果の高い製剤の開発に注視し、医薬品へのアクセスを拡大しようとしています。

経口タンパク質とペプチド市場の成長はいくつかの要因によって牽引されています。

経口タンパク質とペプチド市場の成長は、注射可能な生物製剤に代わる簡便な製剤への需要の高まり、薬剤安定化技術の進歩、慢性疾患におけるペプチドの治療用途の拡大などの要因によってもたらされます。GLP-1アナログやその他の代謝治療薬の採用が増加していることが、経口ペプチド送達プラットフォームに対する商業的関心を煽っています。

バイオアベイラビリティ向上剤、保護コーティング、腸管吸収モデルの進歩が、外来でのペプチド治療の適用拡大を後押ししています。臨床パイプラインの拡充は、良好な患者嗜好や新たな規制当局の承認と相まって、長期的な市場成長のための強固な基盤となっています。バイオテクノロジー企業とデリバリーテクノロジー企業との戦略的パートナーシップは、この進化する分野におけるイノベーションのペースをさらに加速させています。

セグメント

薬物タイプ（カルシトニン薬物タイプ、インスリン薬物タイプ、リナクロチド薬物タイプ、オクトレオチド薬物タイプ、プレカナチド薬物タイプ）、用途（骨疾患用途、糖尿病用途、胃・消化器疾患用途、ホルモン疾患用途）

調査対象企業の例

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37601

Global Oral Proteins and Peptides Market to Reach US$2.0 Billion by 2030

The global market for Oral Proteins and Peptides estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Calcitonin Drug Type, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$762.5 Million by the end of the analysis period. Growth in the Insulin Drug Type segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.6 Million While China is Forecast to Grow at 11.3% CAGR

The Oral Proteins and Peptides market in the U.S. is estimated at US$351.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$411.9 Million by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Oral Proteins and Peptides Market - Key Trends & Drivers Summarized

Why Has Oral Delivery of Proteins and Peptides Remained Technically Difficult?

Proteins and peptides are sensitive biological molecules with poor intrinsic stability in the digestive system. When administered orally, they face rapid degradation by gastric enzymes and harsh pH conditions, followed by limited intestinal absorption due to large molecular size and hydrophilicity. These barriers have historically limited oral use of therapeutic proteins, pushing most into parenteral routes. However, recent scientific progress is making oral delivery more plausible, driving new investment in peptide-based oral drug development.

The motivation behind oral delivery is strong, particularly for long-term treatments like diabetes, growth disorders, and hormonal deficiencies. Patients prefer oral therapies over injections for convenience, comfort, and reduced risk of injection-related complications. Hence, the pharmaceutical industry is actively working on approaches to stabilize peptide structures and promote mucosal transport for systemic absorption.

What Formulation Techniques Are Enabling Systemic Uptake via the GI Tract?

Several formulation strategies are under active development to enable oral delivery of peptides and proteins. Use of enteric-coated capsules and enzyme inhibitors helps protect the drug until it reaches the intestine. Absorption enhancers such as medium-chain fatty acids and bile salts are employed to loosen tight junctions in the intestinal lining, temporarily increasing permeability. Carrier systems like nanoparticles, self-emulsifying drug delivery systems (SEDDS), and lipid-based formulations are designed to improve drug solubility and stability.

Technologies such as permeation-enhancing microcontainers, mucoadhesive films, and transcellular transporters are being refined to achieve consistent and safe absorption. Structural modification of peptides, including cyclization and D-amino acid substitution, improves resistance to enzymatic cleavage without affecting biological activity. These methods are allowing more peptide drugs to achieve bioavailability levels sufficient for therapeutic effect.

Which Therapies Are Leading in Development and Where Is Innovation Concentrated?

Diabetes and metabolic disorders are the leading therapeutic segments for oral peptide development. Oral semaglutide, a GLP-1 receptor agonist for type 2 diabetes, is the most notable commercial success, marking a breakthrough in this space. Similar efforts are targeting oral formulations of insulin, parathyroid hormone, and calcitonin for osteoporosis and thyroid-related disorders.

Biopharmaceutical companies are also exploring oral delivery of peptide-based immunotherapies and anti-inflammatory agents for conditions such as rheumatoid arthritis and ulcerative colitis. North America and select European countries are leading innovation due to strong R&D infrastructure and regulatory engagement. Emerging economies are watching closely for cost-effective formulations to broaden access.

Growth in the Oral Proteins and Peptides market is driven by several factors…

Growth in the oral proteins and peptides market is driven by factors such as increasing demand for convenient alternatives to injectable biologics, progress in drug stabilization techniques, and growing therapeutic use of peptides in chronic diseases. Rising adoption of GLP-1 analogs and other metabolic treatments is fueling commercial interest in oral peptide delivery platforms.

Advancements in bioavailability enhancers, protective coatings, and intestinal absorption models are supporting wider application of peptide therapies in outpatient settings. Expansion of clinical pipelines, coupled with favorable patient preferences and emerging regulatory approvals, is creating a strong foundation for long-term market growth. Strategic partnerships between biotech firms and delivery technology companies are further accelerating the pace of innovation in this evolving field.

SCOPE OF STUDY:

The report analyzes the Oral Proteins and Peptides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type, Plecanatide Drug Type); Application (Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application, Hormonal Disorders Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiasma Inc.
  • Entera Bio Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Synergy Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Proteins and Peptides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Non-Invasive Biologic Delivery Spurs Innovation in Oral Protein and Peptide Formulations
    • Advancements in Permeation Enhancers Strengthen Business Case for Gastrointestinal Absorption Technologies
    • Surge in Oral GLP-1 Receptor Agonist Development Throws the Spotlight on Diabetes and Obesity Therapies
    • Increasing Focus on Enzyme and Hormone Replacement Expands Addressable Market for Oral Biologics
    • Progress in Nanotechnology and Carrier Systems Enhances Stability and Bioavailability of Oral Peptides
    • Use of Enteric Coating and Mucoadhesive Polymers Propels Controlled Release Formulation Development
    • Rising Investment in Oral Immunotherapy Supports New Pathways for Allergy and Autoimmune Treatment
    • Expansion of Biopharma Pipelines in Peptides Drives Demand for Alternative Drug Delivery Routes
    • Growing Application in Oncology and Rare Diseases Opens High-Value Market Segments for Oral Peptides
    • Technological Advances in Oral Nanocarriers Enhance Gastrointestinal Uptake and Therapeutic Impact
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Proteins and Peptides Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Proteins and Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Calcitonin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Calcitonin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Insulin Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Insulin Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Linaclotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Linaclotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Octreotide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Octreotide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Plecanatide Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Plecanatide Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Bone Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Bone Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Gastric & Digestive Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Gastric & Digestive Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hormonal Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hormonal Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • CHINA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oral Proteins and Peptides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oral Proteins and Peptides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • INDIA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oral Proteins and Peptides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oral Proteins and Peptides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oral Proteins and Peptides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Oral Proteins and Peptides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Oral Proteins and Peptides by Drug Type - Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Oral Proteins and Peptides by Drug Type - Percentage Breakdown of Value Sales for Calcitonin Drug Type, Insulin Drug Type, Linaclotide Drug Type, Octreotide Drug Type and Plecanatide Drug Type for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Oral Proteins and Peptides by Application - Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Oral Proteins and Peptides by Application - Percentage Breakdown of Value Sales for Bone Diseases Application, Diabetes Application, Gastric & Digestive Disorders Application and Hormonal Disorders Application for the Years 2014, 2025 & 2030

IV. COMPETITION